IP Library Granted Patent US 11,447,499
Granted Patent B2
US 11,447,499 · App. 16/898,794 · Granted Sep 20, 2022

Process for the preparation of eribulin mesylate intermediate

Inventors: Ravishanker Kovi (Monroe Township, NJ); Jayaraman Kannappan (Vadodara, IN); Shivnath Sahebrao Patil (Dhule, IN)
Assignee: RK PHARMA INC.
C07D493/22
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,447,499
App. No.
16/898,794
Granted
Sep 20, 2022
Kind
B2
Abstract

The present application provides improved processes for the synthesis of eribulin intermediate, which generally comprise the steps of: a) De-protecting the eribulin-enone (compound 1) in tetrahydrofuran by using TBAF solution, buffered with imidazole HCl in the presence of molecular sieve and sodium sulphate to get an insitu mixture of eribulin-dione diastereomer at C12 carbon (compound 2). Then ketalization may be performed of eribulin-dione insitu intermediate containing mixture of diastereomer at C12 carbon (compound 2) with PPTS in dichloromethane to yield eribulin-diol (compound 3).

Claims (7)

1. A process for producing eribulin-diol consisting of:

de-protecting eribulin-enone (compound 1) using 20 eq. of a TBAF solution,

buffering the deprotected eribulin-enone (compound 1) using 10 eq. imidazole HCl in the presence of a mixture of anhydrous molecular sieves and sodium sulphate which is preheated at 110-120° C. for at least 30 minutes,

further cooling the de-protected eribulin-enone (compound 1) to 0-5° C.,

charging the cooled de-protected eribulin-enone (compound 1) with a solution containing imidazole hydrochloride in the TBAF solution and stirring for 24 hours between 10-20° C.,

further filtering and distilling the residue with the addition of methanol and water in the ratio of about 9:1 therewith producing an in situ mixture of eribulin-dione diastereomer at C12 carbon (compound 2); and

performing ketalization of the in situ mixture of eribulin-dione diastereomer at C12 carbon, therewith producing 70% pure eribulin-diol (compound 3).

Assignments (3)
SECURITY INTEREST Recorded May 8, 2024
From: RK PHARMA INC.
To: CITIBANK, N.A.
Reel/Frame 067343/0089 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2022
From: RK PHARMA SOLUTIONS LLC
To: RK PHARMA INC
Reel/Frame 060263/0406 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 18, 2020
From: KOVI, RAVISHANKER; KANNAPPAN, JAYARAMAN; PATIL, SHIVNATH SAHEBRAO
To: RK PHARMA SOLUTIONS LLC
Reel/Frame 054690/0865 →
Priority Claims (1)
IN 201921023560 · Jun 14, 2019 · national
Continuity (1)
Related Publication 20210040107A1 · Feb 11, 2021